← Back to Search

Angiotensin II Receptor Blocker

Telmisartan for Graft-versus-Host Disease

N/A

Waitlist Available

Led By Scott Rowley, MD

Research Sponsored by Hackensack Meridian Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 180 days post- transplant

Awards & highlights

Study Summary

This trial is testing whether the drug telmisartan can help to prevent a complication called acute GVHD in people undergoing a stem cell transplant for treatment of blood cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 180 days post- transplant

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~180 days post- transplant

This trial's timeline: 3 weeks for screening, Varies for treatment, and 180 days post- transplant for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of subjects with grade 3 or greater acute graft vs. host disease (GVHD) in patients receiving allogeneic HCT.

Secondary outcome measures

Number of subjects with Grade III-IV hypotension as per the National Cancer Institute's Common Terminology

Side effects data

From 2016 Phase 4 trial • 33 Patients • NCT02079805

12%

Nasopharyngitis

Diabetic retinopathy

Back pain

Blood pressure decreased

Spinal osteoarthritis

100%

80%

60%

40%

20%

Study treatment Arm

Azilsartan 20 mg

Telmisartan 40 mg

Trial Design

1Treatment groups

Experimental Treatment

Group I: 160 mg TelmisartanExperimental Treatment1 Intervention

60 patients will receive 160 of Telmisartan (2 80 mg tablets) for 101 days

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Telmisartan

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Hackensack Meridian HealthLead Sponsor

131 Previous Clinical Trials

28,212 Total Patients Enrolled

Scott Rowley, MDPrincipal InvestigatorHackensack Meridian Health

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the eligibility criteria of this experiment limited to adults over 35 years of age?

"According to the listed criteria, those who are between 18 and 99 years old can qualify for participation. For minors under 18 or seniors over 65, there are 4 studies available as well as 23 other trials respectively."

Answered by AI

Is this clinical investigation still open for patient enrollment?

"It appears that, per the clinicaltrials.gov database, this specific trial is no longer recruiting participants; it was initially posted on July 7th 2015 and last modified on September 2nd 2022. Nonetheless, there are 23 other trials actively searching for patients at present."

Answered by AI

Who is able to partake in this trial based on the qualification criteria?

"To meet the eligibility requirements of this trial, applicants must have gvhd and be between 18 - 99 years old. 32 participants will ultimately be admitted into the study."

Answered by AI

To which maladies is Telmisartan typically administrated?

"Telmisartan is often prescribed to treat cardiovascular events, but this medication also has off-label uses for treating diabetic nephropathy, hypertensive disease, and those without prior treatment."

Answered by AI

What is the total enrollment of this medical experiment?

"Unfortunately, this study is no longer open for recruitment. It was first posted on July 7th 2015 and last updated September 2nd 2022. If you're looking to join a different trial, there are 11 clinical studies targeting gvhd patients and 12 trials concerning Telmisartan that have openings still available."

Answered by AI

Recent research and studies

Bone Marrow TransplantationJournal

Regulatory T Cell Expression of CLA or Α4β7 and Skin or Gut Acute GVHD Outcomes

Engelhardt, B G, M Jagasia, B N Savani, N L Bratcher, J P Greer, A Jiang, A A Kassim, et al.. 2010. “Regulatory T Cell Expression of CLA or Α4β7 and Skin or Gut Acute GVHD Outcomes”. Bone Marrow Transplantation. Springer Science and Business Media LLC. doi:10.1038/bmt.2010.127.

AtherosclerosisJournal

Anti-inflammatory and Anti-oxidant Properties of Telmisartan in Cultured Human Umbilical Vein Endothelial Cells

Cianchetti, Silvana, Alessandra Del Fiorentino, Renato Colognato, Rossella Di Stefano, Ferdinando Franzoni, and Roberto Pedrinelli. 2008. “Anti-inflammatory and Anti-oxidant Properties of Telmisartan in Cultured Human Umbilical Vein Endothelial Cells”. Atherosclerosis. Elsevier BV. doi:10.1016/j.atherosclerosis.2007.09.013.

BloodJournal

A Critical Role for the Retinoic Acid Signaling Pathway in the Pathophysiology of Gastrointestinal Graft-versus-host Disease

Chen, Xiao, Joseph Dodge, Richard Komorowski, and William R. Drobyski. 2013. “A Critical Role for the Retinoic Acid Signaling Pathway in the Pathophysiology of Gastrointestinal Graft-versus-host Disease”. Blood. American Society of Hematology. doi:10.1182/blood-2012-08-445130.

Expert Opinion on Emerging DrugsJournal